Patent ID: 11931422
Assignee: HELIX BIOPHARMA CORP.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 25:
26. A pharmaceutical aqueous composition for intravenous injection into a subject for treatment of a CEACAM6 expressing tumor, the composition comprising:
a single domain antibody-urease conjugate comprising 6 to 12 single domain antibody moieties per urease moiety, the single domain antibody having an amino acid sequence of SEQ ID NO: 1 that specifically binds to CEACAM6 or an amino acid sequence sharing at least 95% sequence identity with SEQ ID NO: 1 that maintains binding specificity to said CEACAM6, wherein the conjugate has urease activity,
wherein said single domain antibody-urease conjugate has a binding specificity to CEACAM6 about 500 times or higher than an un-conjugated single domain antibody of amino acid SEQ ID NO: 1, and
wherein said composition is substantially free of unconjugated urease.